PCVX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-1.530

+50%

-1.577

+51.68%

-1.605

+31.56%

Estimates Revision

The market is revising No Change the revenue expectations for Vaxcyte, Inc. (PCVX) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 5.38%.

Revenue Estimates for FY2026

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+7.04%

In Past 3 Month

Stock Price

Go Up

+5.38%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast PCVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PCVX is 75.80 USD with a low forecast of 38.00 USD and a high forecast of 116.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

38.00

Averages

75.80

High

116.00

Current: 0.000

Low

38.00

Averages

75.80

High

116.00

Needham

Joseph Stringer

Buy

upgrade

$90 -> $110

2026-01-07

New

Reason

Needham

Joseph Stringer

Price Target

$90 -> $110

2026-01-07

New

upgrade

Buy

Reason

Needham analyst Joseph Stringer raised the firm's price target on Vaxcyte (PCVX) to $110 from $90 and keeps a Buy rating on the shares. The analyst added Vaxcyte to the Needham Conviction List, replacing Phathom Pharmaceuticals (PHAT). Vaxcyte is the firm's top pick for 2026. It is e bullish on the shares 2026 based on the view that the "strongly positive" VAX-31 Phase 2 adult data provided "reasonably good de-risking" for the Phase 3 pivotal readout in Q4. Vaxcyte's pneumococcal vaccine still has best-in-class potential, the analyst tells investors in a research note.

Mizuho

Salim Syed

maintain

2026-01-05

New

Reason

Mizuho

Salim Syed

Price Target

2026-01-05

New

maintain

Reason

Mizuho analyst Salim Syed said the firm is positive on Vaxcyte after the U.S. Department of Health and Human Services approved a revised childhood and adolescent immunization schedule, though there is no change to the pneumococcal conjugate vaccine schedule for children. The Fly notes that Vaxcyte's PCV franchise comprises of both VAX-31 and VAX-24, both of which the company says have the potential to improve upon existing pneumococcal vaccines.

BTIG

Thomas Shrader

Buy

downgrade

$160 -> $85

2025-10-16

Reason

BTIG

Thomas Shrader

Price Target

$160 -> $85

2025-10-16

downgrade

Buy

Reason

BTIG analyst Thomas Shrader lowered the firm's price target on Vaxcyte to $85 from $160 and keeps a Buy rating on the shares. In a broader research note previewing Q3 results for select biotech names, the firm is updating its assumptions and models for the company, the analyst tells investors in a research note.

Goldman Sachs

Neutral

initiated

$38

2025-09-12

Reason

Goldman Sachs

Price Target

$38

2025-09-12

initiated

Neutral

Reason

Goldman Sachs initiated coverage of Vaxcyte with a Neutral rating and $38 price target. The firm believes the company's vaccine-focused platform provided \"validating\" data for its flagship pneumococcal conjugate vaccine franchise over the past three years, positioning Vaxcyte to be a leading player in the \"large and established\" pneumococcal vaccine market. However, an extended timeline to the company's next catalyst, the Phase 3 data in adults in late 2026, along with regulatory uncertainty related to vaccines will cap the stock's performance in the near term, the analyst tells investors in a research note.

TD Cowen

Tara Bancroft

Buy

downgrade

$85 -> $50

2025-08-07

Reason

TD Cowen

Tara Bancroft

Price Target

$85 -> $50

2025-08-07

downgrade

Buy

Reason

TD Cowen analyst Tara Bancroft lowered the firm's price target on Vaxcyte to $50 from $85 and keeps a Buy rating on the shares. The firm is confident that VAX-31 in adults should lead to robust immunogenicity and protection, resulting in a large market. In infants, though TD Cowen is heartened that the Phase II is moving forward with an optimized dose, this extends the data timeline to the first half of 2027. The firm remains confident in the success of the adult and infant programs.

Mizuho

Salim Syed

Outperform

maintain

2025-06-21

Reason

Mizuho

Salim Syed

Price Target

2025-06-21

maintain

Outperform

Reason

Mizuho analyst Salim Syed comments on Outperform-rated Vaxcyte (PCVX) following reports that Health and Human Services Secretary Kennedy is considering a review of licensed vaccines containing aluminum adjuvants. Important to Vaxcyte, its pneumococcal vaccine candidates contain aluminum adjuvant at levels similar to those used in Pfizer's (PFE) Prevnar 20 and Merck's (MRK) Vaxneuvance, the analyst tells investors in a research note. Mizuho says aluminum adjuvants have been widely used since the 1930's and are in numerous vaccines recommended by the Centers for Disease Control and Prevention for infants and children. The FDA has done work showing that aluminum exposure from vaccines is safe, the firm adds. It sees the "preponderance of evidence" as supporting the use of aluminum adjuvants in vaccines, and believes that a review, if done, of licensed vaccines containing aluminum adjuvant "will prove this out."

Valuation Metrics

The current forward P/E ratio for Vaxcyte Inc (PCVX.O) is -7.31, compared to its 5-year average forward P/E of -11.91. For a more detailed relative valuation and DCF analysis to assess Vaxcyte Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-11.91

Current PE

-7.31

Overvalued PE

-7.67

Undervalued PE

-16.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-10.04

Current EV/EBITDA

-5.21

Overvalued EV/EBITDA

-5.09

Undervalued EV/EBITDA

-14.99

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

563.08

Current PS

162.18

Overvalued PS

1671.25

Undervalued PS

-545.09

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

PCVX News & Events

Events Timeline

No data

News

5.0

01-03NASDAQ.COM

Vaxcyte CTO Sells 9,743 Shares Worth Approximately $454,891 Amidst Stock Decline

5.0

01-03Fool

Vaxcyte's CTO Sells 9,743 Shares Valued at Approximately $454,891

6.5

2025-12-22Barron's

This Pharmaceutical Stock Struggled Last Year, But One Analyst Believes It Could Surge 250%.

People Also Watch

Frequently Asked Questions

What is Vaxcyte Inc (PCVX) stock price today?

The current price of PCVX is 46.05 USD — it has increased 1.61 % in the last trading day.

What is Vaxcyte Inc (PCVX)'s business?

Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.

What is the price predicton of PCVX Stock?

What is Vaxcyte Inc (PCVX)'s revenue for the last quarter?

Vaxcyte Inc revenue for the last quarter amounts to -242.38M USD, increased 73.58 % YoY.

What is Vaxcyte Inc (PCVX)'s earnings per share (EPS) for the last quarter?

Vaxcyte Inc. EPS for the last quarter amounts to -155351000.00 USD, increased 57.26 % YoY.

What changes have occurred in the market's expectations for Vaxcyte Inc (PCVX)'s fundamentals?

How many employees does Vaxcyte Inc (PCVX). have?

Vaxcyte Inc (PCVX) has 414 emplpoyees as of January 10 2026.

What is Vaxcyte Inc (PCVX) market cap?

Today PCVX has the market capitalization of 6.03B USD.